DETERA Therapeutics develops disruptive therapies for rare kidney diseases. Its lead candidate, DTR8, is a proprietary first First-In-Class Disease Modifying biopharmaceutical targeting Crescentic Glomerulonephritis, a severe condition with no treatment.
